The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship
作者机构：Baskent University School of MedicineDepartment of Medicine AnkaraAnkara 06810Turkey TC Istanbul Kültür UniversityFaculty of Health SciencesDepartment of NursingIstanbul 34158Turkey Emory University School of MedicineDepartment of MedicineAtlantaGA 30322USA Moffitt Cancer CenterDepartment of Gastrointestinal OncologyTampaFL 33612USA
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2020年第3卷第4期
页 面：699-709页
学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Pancreatic adenocarcinoma durvalumab nivolumab ipilimumab pembrolizumab immune checkpoint inhibitors immunotherapy resistance mismatch repair deficient microsatellite instability high microsatellite stable tumor-associated macrophages myeloid-derived suppressor cells T regs T cells
摘 要：Pancreatic cancer is one of the most aggressive cancers with a high mortality rate even among patients with early-stage *** recent studies with novel therapeutic approaches have led to modest improvement in survival outcomes,limited progress is achieved for the use of immunotherapeutics in this challenging *** checkpoint inhibitors,thus far,single-agent or in combination,have not yielded significant improvement in survival outcomes except in mismatch repair-deficient pancreatic *** tumor microenvironment of pancreatic cancer has been considered as an attractive target for over a decade based on preclinical studies that suggested it may adversely affect drug delivery and antitumor *** this review article,we elaborate on the biology of pancreatic cancer microenvironment,its highly complicated interaction with cancer cells,and the immune *** also discuss plausible explanations that led to the failure of immune checkpoint inhibitors as therapeutic agents and the potential impacts of pancreatic cancer stroma on these negative studies.
维普期刊数据库